Sign in
4

Changes in Ownership

Dyne Therapeutics, Inc. Filed Acc 0001915598-26-000007

Chief Commercial Officer sold 231 shares at $16.82 ($3,885)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Friedl-Naderer Johanna · Chief Commercial Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2026-11-13 Sale : show line 1 in the form 10b5-1 −231 $16.82 $3,885 152,666 D
Open-market sales · 231 sh · avg $16.82 · $3,885
Loading xslF345X06/ownership.xml…